Serum lysophosphatidic acid levels and exacerbation frequency in chronic obstructive pulmonary disease (COPD)

Qingling Li,Andrew Birnberg,Arindam Chakrabarti,David Choy,Erik Verschueren,Margaret Neighbors,Wendy Sandoval,Carrie Rosenberger,Michele Grimbaldeston,Wei Tew
DOI: https://doi.org/10.1183/13993003.congress-2020.5117
2020-09-07
Abstract:<p><b>Introduction:</b> Autotaxin-Lysophosphatidic acid (ATX-LPA) pathway has been associated with inflammatory lung conditions including COPD as it has pleiotropic roles in cell proliferation, lymphocyte homing and fibrosis. ATX functions primarily as lysophospholipase D to generate bioactive lipid LPA detected in blood and inflamed sites.</p><p><b>Aims:</b> We assessed if systemic LPA levels were associated with exacerbation frequency and severity in COPD patients.</p><p><b>Methods:</b> Mass spectrometry assays for LPA species (LPAs) were developed in-house using a custom lipid extraction method, and demonstrated good reproducibility and recovery. LPAs were measured in baseline serum samples from the placebo arm (n=136) of a COPD randomized controlled trial (NCT02546700). The relationship between LPA levels, baseline demographics, and other biomarkers were assessed using Mann-Whitney or Spearman method. Tertile levels of each LPA species were used to assign patients into biomarker high, mid, and low subgroups, and association with on-study exacerbation assessed by a Quasi-Poisson model.</p><p><b>Results:</b> Levels of LPA species were correlated with each other (Spearman rho 0.35 – 0.92), and were influenced by age, gender, region, and exacerbation history. After adjusting for these confounders, patients with the lowest tertile of LPAs had two times higher exacerbation rate in the 6-month follow-up, compared to patients with the highest tertile of LPAs (p&lt;.05). These LPAs were not associated with exacerbation severity (hospitalization) or lung function measures (FEV1, FVC).</p><p><b>Conclusions:</b> These findings provide preliminary support that systemic LPAs are detectable in COPD and associate with exacerbation rate.</p>
What problem does this paper attempt to address?